Despite considerable advances in the treatment of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), 10-20% of children and 460% of adults still fail the available therapies. Hematopoietic stem cell transplantation (HSCT) has contributed to favorable outcomes in high-risk or recurrent ALL in both pediatric and adult populations; however, overt relapses after transplant are currently incurable. Patients at high risk for a subsequent relapse can now be identified by quantification of minimal residual disease (MRD) before transplantation, 2 facilitating assessment of novel strategies to maintain remission and improve prognosis. Adoptive transfer of cytotoxic T cells (CTLs) is one means to enhance the therapeutic potential of HSCT. Although alloreactive donor lymphocytes can exert potent effects against myeloid leukemias, 3 attempts to exploit unmanipulated donor T cells for the treatment of high-risk ALL have had limited success, 3 indicating the lack of immunogenic targets for graft-versus-leukemia responses in this malignancy.
One alternative to harness the cytotoxic potential of T cells is to redirect their specificity to leukemia cells by genetic engineering with chimeric antigen-specific receptors (CARs). CARs consist of an antibody-derived recognition domain, linked to signaling molecules that activate T cells upon interaction with cells expressing the respective target antigen on their surface. 4 CD19 is an attractive target for immunological therapies in BCP-ALL because it is expressed at high densities on most malignant B cells and expression is restricted to the B-cell lineage. CARs against CD19 have now been generated by various groups and have been demonstrated to mediate potent T-cell effector functions against CD19-expressing malignant cells in vitro and in vivo. 5 Specifically, human T cells endowed with CD19-specific CARs have been shown to effectively eradicate human CD19 þ tumor xenografts in immuno-deficient mouse models. 5 So far, in vivo evidence for the antileukemia activity of CD19-specific T cells has been restricted to established tumor cell lines. Primary leukemia cells more closely mimic the heterogeneity of the disease in humans and allow to differentiate between individual subgroups with variable biological risk profiles. In this study, we have investigated the in vivo sensitivity of human leukemic bone marrow (BM) to adoptive immunotherapy with gene-modified CD19-specific T cells.
Unmanipulated BM cells (3-8 Â 10 6 per mice) from pediatric patients at first diagnosis of BCP-ALL were transplanted via intrafemoral injection into 8-12-week-old NOD/scid mice (Charles River Laboratories, Sulzfeld, Germany) without pre-transplant conditioning, as described previously. 6 Leukemia engraftment was monitored by serial BM aspirations from femoral punctures, followed by assessment and quantification of human leukemia cells by flow cytometric analysis of cells within the lymphocyte gate expressing human CD19 and CD45. Among primary leukemia samples from 15 individual patients, 10 were successfully engrafted in at least one NOD/scid mouse within 6 to 20 weeks (Supplementary Table 1 ). In all mice analyzed, the human cells had a BCP phenotype consistent with the original diagnosis. Engraftment of human cells correlated with the development of splenomegaly, indicating that transplanted mice developed overt leukemia. One limitation to using primary leukemia samples for therapeutic experiments is the heterogeneous engraftment and manifestation of the disease in only a proportion of transplanted mice. To develop a more reliable in vivo assay, we performed serial transplantations of the human leukemias into secondary recipients. Although the time to first detection of human leukemia cells in murine BM was not significantly reduced, secondary transplantations ensured subsequent engraftment in four out of four individual primary leukemias. To determine the lowest numbers of primary leukemia cells reliably engrafting secondary murine recipients, a series of titration experiments were performed. Transplantation of minimal numbers of 1 Â 10 4 leukemic cells resulted in engraftment after 3 weeks (Supplementary Figure A) .
As effector cells for CD19-directed adoptive therapy, we chose to use CTLs with native specificity for Epstein-Barr virus (EBV) antigens, as virus-specific donor T cells have a number of potential advantages for subsequent clinical application: EBV-CTLs have been safely administered to 4100 patients to reconstitute EBV-specific immunity after allogeneic HSCT, and they persist and show long-term function without causing graft-versus-host disease (GVHD). 7 Moreover, as EBV-CTLs do not require polyclonal stimulation for efficient retroviral transduction and may receive potent reactivation stimuli in vivo through engagement of the endogenous T-cell receptor (TCR), they may generate persistent memory responses. Indeed, CAR-transduced EBV-CTLs had improved in vivo persistence over polyclonal T cells in a recent clinical study. 8 As a beneficial side effect, adoptive transfer of donor-derived EBV-CTLs will protect the recipient from EBV-associated post-transplant complications. EBV-CTLs were expanded from four healthy donors by coculture with autologous EBV-transformed lymphoblastoid cell lines (LCLs) 7, 8 and transduced to express a CD19-specific CAR (CD19z). CD19z was generated by cloning the variable domains of the heavy and light chains of the monoclonal anti-CD19 antibody FMC63 (provided by H Zola, Adelaide, South Australia, Australia) in frame with a membranespanning domain consisting of human immunoglobulin constant domains CH2 and CH3, and the transmembrane and cytoplasmic domains of the TCR z chain. Costimulatory domains found to enhance the systemic antitumor activity of non-specifically stimulated, CAR-modified T cells 5 were not included, as previous studies have shown that CAR activity in virus-specific CTLs does not benefit from additional signaling elements. 8 For control experiments, an analogous CAR directed against the neuroectodermal antigen G D2 (14.G2az) was used. 8 For gene transfer into CTLs, the CAR transgenes were subcloned into the retroviral vector SFG (provided by RC Mulligan, Cambridge, MA, USA), and stable retroviral producer cell lines were generated by transient production of retrovirus in Phoenix ampho cells (GP Nolan, Stanford, CA, USA) and subsequent infection of the packaging cell line FLYRD18 (E Vanin, Houston, TX, USA) by overnight incubation at 37 1C in the presence of polybrene (4 mg/ml). Viral supernatants were generated on the resulting bulk producer cell lines by adding Iscove's modified Dulbecco medium (GIBCO, Karlsruhe, Germany) supplemented with 20% fetal calf serum, followed by 24 h of incubation at 32 1C. The resulting viral supernatants were filtered (0.45 mm) and used to transduce the EBV-CTLs following their third stimulation with autologous LCLs. Transduction efficiencies were assessed by surface staining of transduced EBV-CTLs with a biotinylated goat anti-mouse antibody specific for the IgG F(ab 0 )2 fragment (Jackson ImmunoResearch, Cambridgeshire, UK) and secondary phycoerythrin-labeled streptavidin antibody (Becton Dickinson, San Jose, CA, USA) ( Figure 1a ). CD19z surface expression in nine transduced CTL lines was 73 ± 21%, range 32-93%, and 14.G2az expression in five lines was 18 ± 13%, range 6-35%. The T-cell lines had a characteristic CTL phenotype, with 95.5 ± 4.9% expressing CD3, of which a mean of 82.3 ± 17.6% coexpressed CD8 (median of 89.7%), while 17.7±17.6% (median of 10.3%) had a T helper phenotype (CD3 þ CD4 þ ). The majority of CD8 þ T cells expressed CD45RO in the absence of CCR7, corresponding to an effector memory T-cell phenotype (Figure 1b ). Immunophenotypes were unaffected by CAR gene expression.
In vitro cytotoxicity experiments by 4-h
51
Cr release assays confirmed specific lysis of the CD19 þ leukemia cell lines REH ( 51 Cr release 59.7±7.2% at an effector:target ratio of 20:1; Figure 1c ) and SupB15 (66.7 ± 8.6; Figure 1d ), in the absence of background lysis by 14.G2az-transduced control CTLs (3.3 ± 3.1% and 4.9 ± 5.0%, respectively) or appreciable cytotoxicity against the CD19À human acute myelomonocytic leukemia cell line ML-2 (14.9 ± 1.9%). CAR-transduced CTLs maintained their cytolytic activity against autologous EBV targets, and 14.G2az-transduced EBV targets effectively lysed tumor target cells expressing the 14.G2a target antigen G D2 (data not shown). To investigate the in vitro sensitivity of primary leukemic cells to CD19-redirected T cells, BM leukemia cells obtained at diagnosis from five pediatric patients with CD19 þ BCP-ALL were used as targets in further cytotoxicity experiments. Primary leukemic cells from all patients were efficiently lysed by allogeneic CD19z-transduced CTLs but not 14.G2az-transduced or non-transduced CTLs from the same donors in vitro (Figure 1d ). Functional interaction of CD19z-transduced CTLs with primary leukemic cells in vitro was further confirmed by specific IFN-g secretion in ELISPOT assays (Figure 1e) .
To analyze the in vivo sensitivity of primary human leukemia to adoptive immunotherapy with CD19z T cells, we focused on a connatal CD19 þ CD10À leukemia, bearing the high-risk feature of an MLL-ENL gene rearrangement due to a t(11;19) translocation. The disease was refractory to standard treatment and fatal before intended allogeneic HSCT. 1 Â 10 4 BM leukemia cells per mouse from one engrafted primary mouse were serially transplanted into a further cohort of 13 NOD/scid mice by secondary intrafemoral transplantation, followed by adoptive transfer of four doses of 5 Â 10 6 CD19z-or 14.G2az-transduced CTLs via tail vein injection on days 1, 4, 8 and 11. Interleukin (IL)-2 (500 IU/mouse) was administered twice weekly. Human leukemia engraftment was monitored in both the CD19z-treated and control groups by flow cytometry analysis of sequential BM aspirates starting 3 weeks after transplantation. Although the human leukemia became detectable in the BM of four of five control mice, followed by overt and fatal leukemia in all cases, five of eight mice receiving transfusions of CD19z-transduced CTLs remained disease-free (P ¼ 0.07, log rank/Mantel-Cox test) and six of eight remained alive, one of them with detectable leukemia cells (P ¼ 0.05; Figure 2 ). As the natural life span in this NOD/scid mouse strain is limited by the development of spontaneous murine thymomas, retransplantation experiments were performed to extend leukemia follow-up. 4 Â 10 6 BM cells obtained from a CD19z-treated mouse were transferred intrafemorally to a further cohort of three 10-weekold mice. All mice remained leukemia-free for a further followup of 8-10 weeks. CTLs were detected in peripheral blood for 2 days (Supplementary Figure B) . Infusions were well tolerated without any clinical or histological signs of toxicity or GVHD. Thus, adoptive transfer of CD19-redirected CTLs can efficiently delay or prevent engraftment of primary human high-risk ALL cells in vivo, encouraging the clinical development of this strategy for patients refractory to standard treatment. The data reported here for the first time extend previous preclinical in vivo experience with established cell lines towards primary human leukemia samples. The attractiveness of this NOD/scid model is based on the observation that NOD/scid repopulating human leukemic cells closely resemble leukemic stem cells (for further literature, see le Viseur et al. 6 ) that carry the capacity to self-renew and repopulate the leukemia. Thus, a maneuver revealing therapeutic activity in this model likely targets not only the bulk of the leukemic blasts but also leukemic stem cells, the most relevant target for novel therapeutic approaches in this disease. However, the adequacy of the in vivo model to predict the clinical activity of donor CD19-redirected T cells against refractory leukemias is still limited. First, there is a narrow experimental window, as engraftment of an individual donor's leukemic cells varies greatly. Even the use of novel, more robust mouse models for human leukemia engraftment, for example, NOD/LtSz-scid IL-2Rgc null mice, cannot easily overcome this limitation. Second, the model is not easily suitable for larger-size experiments, and miscalculated cell load can lead to either no engraftment at all or rapid engraftment with no therapeutic activity (one experiment each with different donors, details not shown). Third, the immuno-deficient, murine BM environment does not allow to study T-cell survival, persistence and memory function, which have emerged from the first clinical studies as major issues for advancing cellular immunotherapies. Finally, the model cannot address the question whether CD19 is the appropriate target to eradicate and cure this leukemia. A recent study has shown that a variety of leukemic cells at different stages of maturation, including both CD19 þ and CD19À cells, can propagate the leukemia in NOD/scid mice. 6 Even though the failure of leukemic BM to engraft in the presence of CD19z T cells and upon retransplantation into untreated mice indicates efficient control of leukemia through controlling CD19 þ leukemic precursors, subsequent re-emergence of the leukemic clone from persisting CD19À leukemia initiating cells cannot be excluded. Addressing these questions will require clinical efficacy studies of CD19-specific T cells in leukemia patients, the first of which are currently being launched. For efficient translation of this strategy into clinical leukemia treatment, optimal integration into current standard chemotherapy and allogeneic HSCT will be of paramount importance. This could include MRD-based timing of immune intervention, measures to overcome the immunosuppressive microenvironment of the leukemic BM, for example, by depletion of regulatory T cells before adoptive T-cell transfer, and vaccination-based approaches to prolong effector cell persistence.
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